The ability of CD40 agonists to stimulate stromal modulation and reorganization via macrophage activity suggests other therapeutic modalities could be enhanced without the immunosuppressive stroma characteristic of pancreatic tumors. The gene discussed is CD40; the disease is pancreatic neoplasm.